{"id":"switch-to-triumeq","safety":{"commonSideEffects":[{"rate":"approximately 5-8%","effect":"Hypersensitivity reaction (abacavir-related)"},{"rate":"approximately 10-15%","effect":"Nausea"},{"rate":"approximately 10-15%","effect":"Diarrhea"},{"rate":"approximately 10-12%","effect":"Headache"},{"rate":"approximately 5-10%","effect":"Insomnia"},{"rate":"approximately 5-10%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Triumeq combines abacavir (a nucleoside reverse transcriptase inhibitor), lamivudine (a nucleoside reverse transcriptase inhibitor), and dolutegravir (an integrase strand transfer inhibitor). These three agents work synergistically to block different steps of the HIV replication cycle, preventing the virus from multiplying and reducing viral load in infected individuals.","oneSentence":"Triumeq is a fixed-dose combination antiretroviral that inhibits HIV reverse transcriptase and integrase to suppress viral replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:10:31.368Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-naïve and treatment-experienced adults"},{"name":"HIV-1 infection in adolescents and children (weight-based dosing)"}]},"trialDetails":[{"nctId":"NCT02938520","phase":"PHASE3","title":"Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2016-10-27","conditions":"HIV Infections","enrollment":631},{"nctId":"NCT04904406","phase":"PHASE4","title":"Changes in Weight, Body Composition and Cardiac Risk After Discontinuing Abacavir Treatment in HIV-infected Individuals","status":"COMPLETED","sponsor":"Thomas Benfield","startDate":"2020-10-22","conditions":"Hiv, HIV Infections, HIV Cardiomyopathy","enrollment":81},{"nctId":"NCT02354053","phase":"PHASE4","title":"Evaluation of Switching From Current cART to Triumeq With Adherence Support Will Enhance HIV Control in Vulnerable Populations","status":"COMPLETED","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2015-11","conditions":"HIV Infections","enrollment":27},{"nctId":"NCT04155554","phase":"PHASE3","title":"Neurological Monitoring in Patients Switching From Dolutegravir Based Regimen to Bictegravir Based Regimen","status":"UNKNOWN","sponsor":"Azienda Ospedaliera Universitaria Senese","startDate":"2020-01-29","conditions":"HIV-1-infection","enrollment":100},{"nctId":"NCT02509195","phase":"PHASE4","title":"SSAT064: Pharmacokinetics of Abacavir/Lamivudine/Dolutegravir in HIV Patients of 60 Years and Over","status":"COMPLETED","sponsor":"St Stephens Aids Trust","startDate":"2015-08-04","conditions":"HIV","enrollment":40},{"nctId":"NCT03275701","phase":"NA","title":"Evaluating BMD in Participants ≥50 Years Old Switching From EVG/COBI/FTC/TAF or EVG/COBI/FTC/TDF to ABC/DTG/3TC","status":"UNKNOWN","sponsor":"Mills Clinical Research","startDate":"2016-07","conditions":"Infection, Human Immunodeficiency Virus","enrollment":50},{"nctId":"NCT02067767","phase":"PHASE2","title":"Multicentric Open-label Study of Switch From Abacavir/Lamivudine Fixed Dose Combination Plus Nevirapine to Abacavir/Lamivudine/Dolutegravir in Virologically Suppressed HIV-1 Infected Adults (SWAD)","status":"COMPLETED","sponsor":"Nantes University Hospital","startDate":"2014-02","conditions":"HIV-1 Infection","enrollment":53}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Switch to Triumeq","genericName":"Switch to Triumeq","companyName":"McGill University Health Centre/Research Institute of the McGill University Health Centre","companyId":"mcgill-university-health-centre-research-institute-of-the-mcgill-university-heal","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Triumeq is a medication used to treat HIV-1 infection. It contains the active ingredients bictegravir, emtricitabine, and tenofovir alafenamide, which work together to inhibit the replication of the virus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}